The management of two multinational pharmaceutical companies has changed on March 1st!

▌ The two business units of Fessen and Huarui merged

According to Dami’s understanding, today, Fresenius Kabi China announced to employees that since March 1st, the Anesthesia and Surgery Division of Beijing Fresenius Kabi Pharmaceutical Co.

The two business units merged into a new "Parenteral Nutrition and Anesthesia Division", and Chen Guang was appointed as the Vice President of Fresenius Kabi China, who is fully responsible for the business operations and personnel management of the new Parenteral Nutrition and Anesthesia Division.

Chen Guang is currently the executive deputy general manager of Fika Huarui.

After this new appointment, Chen Guang will still serve as the executive deputy general manager of Fika Huarui, reporting to the general manager of Fika Huarui Zhuang Wenyan.

Of course, like other multinational pharmaceutical companies in China, Fresenius Kabi’s adjustment is also to adapt to changes in national pharmaceutical policies, optimize product portfolios, and improve operational efficiency.

The German Fresenius Group is a large multinational medical enterprise, composed of four independent business units, which are responsible for their respective global operations: including Fresenius Medical Products Company, Fresenius Kabi, and Fresenius Schilius and Fresenius Omed.

Among them, Fresenius Kabi is a multinational enterprise specializing in the field of infusion, blood transfusion and clinical nutrition.

As early as the 1980s, Fresenius Kabi started its business in China.

Fika Huarui's predecessor, Huarui Pharmaceutical, was established in 1982.

At the beginning of 2016, Beifei and Huarui began preparations for a merger in Beijing.

▌ Ji Cheng was transferred to the head of Novartis Pharmaceuticals (China) Hong Kong

Not only Fresenius Kabi, but Dami understands that the management staff of Novartis, another multinational pharmaceutical company, will also change next month.

Yesterday, Novartis Pharmaceuticals announced that it had appointed Ji Cheng as the head of Novartis Pharmaceuticals (China) Hong Kong, reporting directly to Wang Jia, the head of Novartis Pharmaceuticals (China) Transplantation and Respiratory Division.

Ji Cheng is currently the head of Novartis Pharmaceuticals (China) business model transformation promotion and digitalization team.

After Ji Cheng was transferred to Hong Kong, his successor has not yet been determined.